Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

141. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events (...) . Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology report no. 133. 2010 Authors' conclusions In patients with ACS without ST-segment elevation, therapy with clopidogrel and ASA was more efficacious than ASA alone, with an increased risk of major bleeding. A post hoc analysis

2010 Health Technology Assessment (HTA) Database.

142. CYP2C19 genotyping to predict response to clopidogrel

CYP2C19 genotyping to predict response to clopidogrel CYP2C19 genotyping to predict response to clopidogrel CYP2C19 genotyping to predict response to clopidogrel Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation CYP2C19 genotyping to predict response to clopidogrel. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2010 Authors' objectives Dual antiplatelet (...) therapy with aspirin and a thienopyridine is recommended both in patients after acute myocardial infarction (MI) and in patients undergoing percutaneous coronary intervention (PCI) procedures with stenting. Every year in the United States, there are approximately 1.3 million inpatient PCIs and 0.9 million patients who experience an MI. Clopidogrel (trade name Plavix®; Sanofi-Aventis Inc.) is the main thienopyridine prescribed for antiplatelet therapy; in 2009, the Food and Drug Administration (FDA

2010 Health Technology Assessment (HTA) Database.

143. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial

Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Thurston SJ, Heeg B, de Charro F, van Hout B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of combined treatment with clopidogrel and aspirin compared with aspirin alone, for patients with ST-segment elevation myocardial infarction. The authors concluded that clopidogrel, combined with aspirin and given according to the Clopidogrel as Adjunctive Reperfusion

2010 NHS Economic Evaluation Database.

144. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK

A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK Karnon J, Holmes MW, Williams R, Bakhai A, Brennan A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study aimed to assess the incremental cost-effectiveness of treatment for one month or for one year, with clopidogrel in addition to standard therapy, for patients diagnosed with ST-segment elevation myocardial infarction, in the UK. The authors concluded that the addition of clopidogrel to standard therapy was cost

2010 NHS Economic Evaluation Database.

145. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasug (Full text)

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasug Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition (...) With Prasugrel - Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel - Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ Record Status This is a critical

2010 NHS Economic Evaluation Database. PubMed

146. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

147. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis

New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

148. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80) Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome | Guidance | NICE Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Technology appraisal guidance [TA80] Published date: 28 July 2004 Guidance This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in and by recommendation 1.3.18 in . Explore © NICE [year]. All rights reserved. Subject to .

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

149. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210) Overview | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | Guidance | NICE Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events Technology appraisal guidance [TA210] Published date: 15 December 2010 Share Guidance on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events (...) in adults. Persantin Retard and Asasantin Retard have been discontinued, but generic versions of modified-release dipyridamole with and without aspirin are available. Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Guidance development process This guidance replaces NICE technology appraisal guidance on clopidogrel and modified-release

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

150. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

151. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis

Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

152. DuoCover - clopidogrel / acetylsalicylic acid

DuoCover - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/195986/2010 CHMP ASSESSMENT REPORT FOR DuoCover International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001144 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) indication: DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoCover is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction in medically treated

2010 European Medicines Agency - EPARs

153. DuoPlavin - clopidogrel / acetylsalicylic acid

DuoPlavin - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/196090/2010 CHMP ASSESSMENT REPORT FOR DuoPlavin International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001143 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) for the following indication: DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction

2010 European Medicines Agency - EPARs

154. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty (Full text)

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).A 600-mg loading dose of clopidogrel compared with 300 mg provides more rapid and potent inhibition of platelet (...) activation.In the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, 3,602 patients with STEMI undergoing primary PCI were randomized to bivalirudin (n = 1,800) or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (n = 1,802). Randomization was stratified by thienopyridine loading dose, which was determined before random assignment.Patients in the 600-mg (n = 2,158) compared with the 300-mg (n = 1,153) clopidogrel loading dose group had

2009 EvidenceUpdates PubMed

155. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention (Full text)

Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention Inhibition of platelet aggregation after aspirin or clopidogrel intake varies greatly among patients, and previous studies have suggested that poor response to oral antiplatelet agents may increase the risk of thrombotic events, especially after coronary angioplasty. Whether this reflects suboptimal platelet inhibition per se, which might benefit (...) from more potent antiplatelet agents such as tirofiban, is unknown.We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease. Patients were randomly assigned in a double-blind manner to receive either tirofiban (n=132) or placebo (n=131) on top of standard aspirin and clopidogrel therapy. The primary end point

2009 EvidenceUpdates PubMed

156. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again (...) . >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Study found that 12 months of treatment with clopidogrel seems to be cost-effective in both 'average' patients and higher-risk patients, while for lower-risk patients, treatment beyond 3 months does

2009 NIHR HTA programme

157. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardi (Full text)

Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardi Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. This effect must be balanced (...) against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI.We studied 13 608 patients with acute coronary syndrome undergoing percutaneous coronary intervention randomized to prasugrel or clopidogrel and treated for 6 to 15 months in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI

2009 EvidenceUpdates PubMed

158. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel (Full text)

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown.We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction (...) . The cases in our study were those readmitted with acute myocardial infarction within 90 days after discharge. We performed a secondary analysis considering events within 1 year. Event-free controls (at a ratio of 3:1) were matched to cases on age, percutaneous coronary intervention and a validated risk score. We categorized exposure to proton pump inhibitors before the index date as current (within 30 days), previous (31-90 days) or remote (91-180 days).Among 13 636 patients prescribed clopidogrel

2009 EvidenceUpdates PubMed

159. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial (Full text)

Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus (...) rhythm.This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of

2009 EvidenceUpdates PubMed

160. Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction (Full text)

Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction The primary objective of this study was to compare the effect of therapy with bivalirudin alone versus bivalirudin plus eptifibatide on platelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-fibrin clot strength (TIP-FCS) measured by thrombelastography in percutaneous coronary (...) intervention (PCI) patients. The secondary aim was to study the relation of platelet aggregation and TIP-FCS to the occurrence of periprocedural infarction.Bivalirudin is commonly administered alone to clopidogrel naïve (CN) patients and to patients on maintenance clopidogrel therapy (MT) undergoing elective stenting. The effect of adding eptifibatide to bivalirudin on platelet reactivity (PR) and TIP-FCS, and their relation to periprocedural infarction in these patients are unknown.Patients (n = 200

2009 EvidenceUpdates PubMed